The tweet was deleted by the author.
But we saved everything 🙂.
CVRx announced its financial results for the third quarter, posting total revenue of 13.8 million dollars. U.S. revenue accounted for 13.0 million dollars during the period.
The number of active U.S. implanting centers rose to 262, up from 250 previously. The company also provided a business outlook for 2026, highlighting recent operational milestones.
View post on X Loading...
CVRx recently supported Endeavor Health’s first Barostim procedure to expand heart failure treatment options. The company also reported the first BENEFIT-HF trial participant implanted in Ohio by The Christ Hospital team. These developments mark steps in advancing Barostim therapy and clinical research initiatives.